Markus F Neurath
4 min
Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, remain difficult to treat for many patients who fail to respond to conventional biologics or small-molecule therapies. This paper explores the potential of chimeric antigen receptor (CAR) cellular therapies—a technology successfully used in oncology—as a strategy to achieve sustained immune recalibration in IBD. The approach shifts the focus from broad pathway inhibition to the precise targeting of specific immune cell populations.
CAR-T cells are engineered to recognize specific surface antigens, such as CD19, allowing them to bypass traditional immune activation pathways. In the context of ulcerative colitis, there is growing evidence that mucosal B cells and plasmablasts contribute to disease chronicity. While traditional anti-CD20 therapies (like rituximab) have shown limited success in IBD, they often fail to deplete these tissue-resident plasma cells. CD19-directed CAR-T cells offer a more potent alternative, capable of deep depletion of these pathogenic cells. A recent case report of a patient with multirefractory ulcerative colitis achieving drug-free remission after CD19-directed therapy provides a significant proof-of-concept for this strategy.
Unlike cytotoxic CAR-T cells, CAR regulatory T cells (CAR Tregs) are designed to suppress inflammation rather than eliminate cells. By engineering Tregs to recognize specific antigens, researchers aim to concentrate their suppressive activity within the inflamed intestinal mucosa. A particularly promising strategy involves targeting the IL-23 receptor, which is central to the Th17-driven inflammation often seen in Crohn's disease. This approach could potentially resolve local inflammation without the risks associated with systemic immunosuppression.
While these technologies represent a major conceptual shift, they are not intended to replace standard therapies for early-stage disease. Instead, they are targeted at refractory endotypes where other treatments have failed. Significant hurdles remain, including the high cost, complex manufacturing requirements, and the need to ensure the safety of these cells in the sensitive gut environment. Future research must focus on optimizing these therapies to avoid damaging the intestinal barrier while ensuring long-term immune stability.
Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are therapeutically challenging chronic inflammatory diseases of the intestine. Despite major advances in biologic and small-molecule therapies, many patients with IBD experience primary nonresponse, secondary loss of response, or severe complications, underscoring the need for innovative therapeutic strategies that lead to sustained immune recalibration. Chimeric antigen receptor (CAR)-based cellular therapies represent an emerging new concept for transformative medicine. These CAR-T cells are engineered to recognise defined surface antigens, such as CD19, and are therefore ideally suited to eliminate selected pathogenic immune cell populations, such as B lymphocytes. In IBD, this concept has gained momentum through evidence implicating mucosal B cells, plasmablasts, and disease-associated humoral responses as potential disease drivers in UC. A recent case report suggested that CD19-directed CAR-T cell therapy may induce profound remission in multirefractory UC. In parallel, CAR regulatory T cells (CAR Tregs) may offer a complementary approach for IBD therapy by redirecting suppressive immune function in the inflamed intestine. Particularly, interleukin-23 receptor-targeted CAR Tregs provide a mechanistically attractive strategy to modulate T helper-type 17-driven mucosal inflammation in CD. Safety considerations and translational challenges are potential concerns with regard to CAR-T and CAR-Treg therapies in IBD. However, these technologies may enable precision immune engineering for selected refractory disease endotypes in IBD.
Sam: And if that works, you potentially sidestep both the manufacturing bottleneck and the lymphodepletion requirement. Does that change who is eligible?
Alex: Possibly, but there is a significant unresolved question first: whether these cells can maintain their phenotype and function within the inflammatory milieu of the gut. Sustained exposure to IL-6, TNF, and the other cytokines abundant in active IBD can drive T cell exhaustion or phenotypic drift. That is not a trivial problem to solve.
Sam: So the cytotoxic CD19-directed approach is one arm of this. What is the other? [[RP_SECTION:regulatory-t-cell-approaches|Regulatory T cell approaches]]
Alex: CAR-Tregs—regulatory T cells engineered with chimeric antigen receptors. Where CAR-T cells are designed for deletion of pathogenic populations, CAR-Tregs are designed to restore localised tolerance. One target the review highlights is the IL-23 receptor, which sits upstream of Th17-driven pathology. The idea is that rather than eliminating cells, you reprogram the local immune environment to become permissive of tolerance again. These two strategies are not competing—they address different immunological problems and may ultimately be complementary.
Sam: So the framing here is not just a more potent inhibitor. It is a transition from broad systemic suppression toward antigen-specific, tissue-localised immune reprogramming.
Alex: That is the shift the review is arguing for. The goal is not another drug that blunts the immune response globally, but tools that can be programmed to act precisely where the disease is active—and, in the best case, leave a durable imprint that persists after the intervention ends. Whether the current clinical evidence is strong enough to support that framing at scale is still an open question, but the mechanistic rationale is clear. Thanks for listening to ResearchPod.